|
| DRUG REVIEW |
|
| Year : 2014 | Volume
: 60
| Issue : 3 | Page : 300-302 |
Bedaquiline: A novel antitubercular drug for multidrug-resistant tuberculosis
H Nagabushan, HS Roopadevi
Department of Pharmacology, Mandya Institute of Medical Sciences, Mandya, Karnataka, India
Correspondence Address:
Dr. H Nagabushan
Department of Pharmacology, Mandya Institute of Medical Sciences, Mandya, Karnataka
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0022-3859.138772
Multidrug-resistant and extensively drug-resistant tuberculosis (TB) are emerging global health threats. Bedaquiline is a new antituberculous drug belonging to the diarylquinoline class that efficiently inhibits the adenosine triphosphate synthase enzyme of Mycobacterium tuberculosis. It is a bactericidal and long-acting drug. It inhibits both dormant as well as replicating bacterial sub-populations and thus shortens the duration of TB treatment. This drug has been approved by the Food and Drug Administration in December 2012 for the management of multidrug resistant-TB. The drug marks the introduction of a new addition to the TB armamentarium after four decades.
[FULL TEXT] [PDF]*
|
